In recent years, immunotherapy represented by anti-PD1 therapy has shown promising therapeutic potential in partial preclinical research of glioma [81, 82]; however, most clinical trials of immunotherapy have failed to achieve the expected treatment efficacy [83], and the clinical benefit of ICIs therapy to glioma patients is highly heterogeneous. This evidence concerns the gene PDCD1 and glioma.